Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 14/20 | 0.40 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.40 |
| ▸ | STIM1 | Q13586 | 2/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30443348 | 1.00 | USP1 (0.40) | USP1WDR48STIM1ORAI1NR3C2 | |
| SCHEMBL30693863 | 0.79 | USP1 (0.45) | USP1 | |
| SCHEMBL27088186 | 0.79 | USP1 (0.45) | USP1 | |
| SCHEMBL25184227 | 0.79 | USP1 (0.67) | USP1WDR48 | |
| SCHEMBL30443076 | 0.79 | USP1 (0.67) | USP1WDR48 | |
| SCHEMBL29296052 | 0.77 | USP1 (0.40) | USP1 | |
| SCHEMBL30443641 | 0.76 | USP1 (0.43) | USP1WDR48STIM1ORAI1 | |
| SCHEMBL25184831 | 0.76 | USP1 (0.43) | USP1WDR48STIM1ORAI1 | |
| SCHEMBL29296058 | 0.76 | USP1 (0.41) | USP1WDR48 | |
| SCHEMBL30032070 | 0.76 | USP1 (0.39) | USP1WDR48 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083297-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | USP1 1/4885WDR48 660/4885STIM1 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.